Pliant Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Pliant Therapeutics Inc reported a quarterly adjusted loss of 43 cents per share for the quarter ended September 30, an improvement from a loss of 95 cents in the same quarter last year. The reported revenue was zero, matching analyst expectations. The company incurred a quarterly loss of $26.3 million. Pliant's shares rose 3.4% this quarter but have lost 88.4% year-to-date. Analysts maintain a "hold" rating, with a median 12-month price target of $3.00, 49% above the last closing price of $1.53.